Press

Intervacc AB (publ) announces that Strangvac^®, the company’s innovative vaccine against strangles in horses, has been approved by the authorities in Iceland.

Intervacc AB (publ) announces that the company's 2025 Annual Report has been published today. The annual report (in Swedish) is attached and an English unaudited translation of the report is available for download on ... Read more

The shareholders of Intervacc AB (publ), reg. no. 556238-1748 (the “Company”), are hereby invited to the Annual General Meeting (“AGM”) to be held on Wednesday 13 May 2026 at 3.00 p.m. at Cirio Advokatbyrå, ... Read more

Intervacc AB (publ) is first in the world to show that piglets were protected against the virulent and severe disease-causing S. suis Sequence Types 1 and 16 (serotype 2 and 9, respectively), by vaccinating ... Read more

The Board of Directors of Intervacc AB (publ), together with Jonas Sohlman, has agreed that he will leave his role as Chief Executive Officer and Group CEO.

Simultaneously, the Board has appointed Carl-Johan ... Read more